Home / Pressrelease

Interim report period from January 2018 to June 2018


  • Operating loss KSEK -3,563 (-2,559)
  • Loss per share SEK -0.04 (-0.12)

2018 FIRST HALF YEAR (Jan-Jun)

  • Operating loss KSEK -6,385 (-5,240)
  • Loss per share SEK -0.07 (-0.25)
  • On March 22nd , the Company informed that it is close to obtaining CE mark for VagiVital®. This after the Company has received the report of the evaluation of its so called Technical File. The evaluation has been performed by Lloyd’s Register Quality Assurance, Ltd. (LRQA) in England, acting as the Notified Body. The Company submitted the Technical File in January.
  • At the AGM On March 28th, all Board Members were re-elected.
  • On April the 10th, Peptonic Medical announced its plans for a partly underwritten rights issue of 12.5 MSEK with pre-emptive rights for existing shareholders. Issue price was set at 0.29 SEK per share.
  • On April the 24th, the company announced that it has entered an agreement for the commercial supply of its hormone-free selfcare product VagiVital® with Orion Corporation (‘Orion’), with headquarters in Espoo, Finland. The supply agreement is non-exclusive and a result of a successful transfer of the manufacturing technology under the technology transfer agreement signed by the two companies in December 2017.
  • On May the 8th, the Company announced that the rights issue had been heavily oversubscribed. In total, the Company raised 12.5 MSEK before cost.
  • On May the 31st, the Company announced that its first-to-be-launched product - VagiVital® - has received the CE Mark from Lloyd’s Register Quality Assurance, Ltd. (LRQA) in England, acting as the Notified Body for the product. This means that the product can be marketed in the entire EU market.
  • On June the 29th, the Company announced that it has entered a distribution agreement for its hormone-free self-care product VagiVital® with Orion Corporation concerning Finland. Orion plans to launch the Product under its own brand name later this year.

  • On July 9th, the Company announced that VagiVital® now can be purchased via its webshop on www.vagivital.se .  


From the CEO

During the first half of this year our focus has been on the preparations for the launch of VagiVital®. We have obtained the CE mark for the product, secured manufacturing capacity and product quality, developed an attractive and selling product design and evaluated different sales channel options. In addition, we have kept searching for distributors outside Sweden.

It is satisfying to see that we have achieved our objectives and targets, which means that we were ready to push the launch button in early July. We decided to start selling VagiVital® via our webshop at www.vagivital.se . This in anticipation of the pharmacy chains’ decision on when VagiVital® will be carried either in the street shops or webshops.

During this autumn, we will step up advertising and marketing activities to reach a greater portion of patients and thereby increase traffic to our webshop.

In June we signed the first distribution agreement for VagiVital® outside Sweden. Orion Corporation will become our distributor in Finland and product launch is planned before the end of this year. Hence, we expect a first order from Finland in the near future. Orion will market and sell the product under its own trademark. Discussions with distribution partner candidates for additional territories are underway. All going well, these discussions may result in additional distribution agreements by the end of this year.

In May a rights issue was announced that was subscribed at 170 percent. It generated proceeds of MSEK 12m before costs of SEK 2m. The proceeds will be used for the launch and marketing/promotion of VagiVital®.

The result of the first half of this year showed an increased loss by SEK 1.1m as compared with the same period last year. Cash in bank was SEK 10.5m. During the first half of 2017 net SEK 3.1m of intangible assets were balanced, whereas the corresponding figure for H1 2018 was SEK 0.4m. Hence, the negative cash flow of the going business, including intangible assets, has been reduced by SEK 1.6m. This despite considerable costs for the CE –mark and pre-launch activities during the second quarter 2018 – a rather good performance.

During the coming months we will closely monitor the sales development of VagiVital® and analyse the outcomes of different marketing/promotion activities. We will participate in national meetings to meet with gynaecologists, midwives and representatives of the pharmacy chains. We will actively advertise in the social media and develop alliances with influencers to strengthen our messages to the target patient groups.

Johan Inborr


Stockholm, August 17th, 2018


Peptonic Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.

VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.

For more information: www.peptonicmedical.com

About VagiVital®

VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.

Peptonic Medical has launched VagiVital® as a non-prescription self-care product in 2018. For more information: www.vagivital.com


Net sales – Currently the company has no sales.

Costs – Costs for the second quarter were KSEK -3,563 (-2,559). Costs for the first half year were KSEK

-6,319 (-5,240).

Result – Loss before taxes for the second quarter was KSEK -3,589 (-2,592). Loss before taxes for the first half year was KSEK -6,347 (-5,273).

Financial position and liquidity – Liquid assets were KSEK 10,534 (3,333) as of June 30, 2018.

Equity – The equity amounted to KSEK 64,345 (56,369) as of June 30, 2018. 93 (90) percent of which is shareholders funds.

Organization – The average number of employees during the period was 2 (2). At the end of the period the number of employees was 2 (2).

Share – Total numbers of shares in the company amounted to 86,028,600 (20,602,984), as of June 30, 2018.

Download file
Interim report period from January 2018 to June 2018

Contact us

Please contact us if you would like to know more about PEPTONIC medical or Vagivital™.

Contacts »